Clinical trial
Late Phase 2 Study of OPC-12759 Ophthalmic Suspension
NCT00475319 · Otsuka Pharmaceutical Co., Ltd., Industry · Completed
Key facts
| NCT number | NCT00475319 |
|---|---|
| Title | Late Phase 2 Study of OPC-12759 Ophthalmic Suspension |
| Official title | Late Phase 2 Study of OPC-12759 Ophthalmic Suspension |
| Lead sponsor | Otsuka Pharmaceutical Co., Ltd., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Dry Eye Syndromes |
| Intervention type | Drug |
| Interventions | placebo, 1% OPC-12759 ophthalmic suspension, 2% OPC-12759 ophthalmic suspension |
| Enrollment | 308 |
| Start date | May 1, 2007 |
| Primary completion | Mar 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | May 21, 2007 |
| Last update posted | Jun 13, 2013 |
| Countries | Japan |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: